We evaluated the in vitro activity of plazomicin against other aminoglycosides in 122 clinical carbapenem-resistant Enterobacteriaceae isolates using several clinical susceptibility breakpoints. Plazomicin had excellent in vitro activity with 98% overall susceptibility. Amikacin was the next most active with 86% overall susceptibility. This dropped to 55% when switching from Clinical Laboratory and Standards Institute to US Committee on Antimicrobial Susceptibility Testing breakpoints.
Keywords: Aminoglycoside resistance; Carbapenem-resistant Enterobacteriaceae; Plazomicin; Susceptibility testing.
Copyright © 2020 Elsevier Inc. All rights reserved.